Repeated intratumoral injections of CAR-modified T cells specific to erbB-2 accumulated cells at tumor sites have eliminated tumor cells as well as prevented relapse in a mouse spontaneous mammary tumor model due to overexpression of the human erbB-2 transgene [120]. This evidence concerns the gene ERBB2 and breast cancer.